A 57-Year-Old Woman with HR+/HER2- Metastatic Breast Cancer

home / case-based-peer-perspectives / a-57-year-old-woman-with-hr-her2-metastatic-breast-cancer

Centering discussion on a patient case of metastatic breast cancer, expert oncologist Hope Rugo, MD, FASCO, highlights systemic therapy selection and best practices in this setting.

Hope Rugo, MD, FASCO, an expert on breast cancer

EP. 1: Case Overview: A 57-Year-Old Woman with HR+/HER2- Metastatic Breast Cancer

Hope S. Rugo, MD
March 22nd 2023

Expert oncologist Hope Rugo, MD, FASCO, reviews the diagnosis and treatment of a 57-year-old woman with HR+/HER2- metastatic breast cancer (mBC).

Watch

Hope Rugo, MD, FASCO, an expert on breast cancer

EP. 2: The Role of ESR1 Mutations and Approaches to Biomarker Testing in Endocrine-Resistant Breast Cancer

Hope S. Rugo, MD
March 22nd 2023

Expert perspective on the role of ESR1 mutations in HR+/HER2- mBC and best practices on biomarker testing for patients experiencing disease progression on endocrine therapy.

Watch

Hope Rugo, MD, FASCO, an expert on breast cancer

EP. 3: Treatment Options for HR+/HER2- Metastatic Breast Cancer with Disease Progression on Standard-of-Care Therapy

Hope S. Rugo, MD
March 22nd 2023

A comprehensive review of treatment options for patients with HR+/HER2- metastatic breast cancer who experience disease progression on standard-of-care therapies such as combination CDK4/6 and aromatase inhibitors.

Watch

Hope Rugo, MD, FASCO, an expert on breast cancer

EP. 4: Elacestrant Therapy in HR+/HER2- Metastatic Breast Cancer: The EMERALD Trial

Hope S. Rugo, MD
March 22nd 2023

Centering discussion on the EMERALD trial, Dr Hope Rugo, reflects on the safety and efficacy of elacestrant in patients with HR+/HER2- mBC.

Watch

Hope Rugo, MD, FASCO, an expert on breast cancer

EP. 5: Selecting Optimal Second- and Third-Line Therapy for HR+/HER2- mBC

Hope S. Rugo, MD
March 22nd 2023

Dr Hope Rugo shares insight on how she approaches second-line and higher treatment selection in patients with HR+/HER2- metastatic breast cancer who experience disease progression on first-line therapy.

Watch

Hope Rugo, MD, FASCO, an expert on breast cancer

EP. 6: HR+/HER2 Metastatic Breast Cancer: Future Directions in Care

Hope S. Rugo, MD
March 22nd 2023

Closing out her discussion on the treatment and management of HR+/HER2- mBC, Hope Rugo, MD, FASCO, highlights unmet needs and future directions in the field.

Watch